arrow
A

Alessandra Boccaccino

ausl della romagna
H指数:23
被引数:1,916

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinicopathological features of mismatch repair-deficient colorectal cancer: an observational experience from Romagna, Italy

错配修复缺陷型结直肠癌的临床病理特征:来自意大利艾米利亚-罗马涅地区的观察经验

2026-01-010
PRE
Genomic Pathway Alterations and Their Prognostic Impact in Biliary Tract Cancer: Insights from a Multinational Cohort Treated with Cisplatin, Gemcitabine, and Durvalumab

基因组通路改变及其在胆道癌中的预后影响:来自接受顺铂、吉西他滨和度伐利尤单抗治疗的跨国队列的见解

2025-10-030
PRE
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population

接受顺铂、吉西他滨和度伐利尤单抗治疗的晚期胆道癌患者中分子改变的影响:一项大型、真实世界、全球性人群研究

2025-09-011
PRE
Prognostic impact and clinical management of pT4N0 colon cancer: data from a large, multicenter, international, real-world dataset

pT4N0结肠癌的预后影响与临床管理:来自大型、多中心、国际、真实世界数据集的数据

2025-07-150
OAAI
Unveiling the prognostic significance of malignant ascites in advanced gastrointestinal cancers: a marker of peritoneal carcinomatosis burden
2024-11-040
OAAI
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population

Durvalumab联合吉西他滨和顺铂治疗晚期胆道癌: 大量现实世界人口

2024-09-013
PRE
Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial
2024-02-094
OAAI
Phase II study of capecitabine-based concomitant chemoradiation followed by durvalumab as a neoadjuvant strategy in locally advanced rectal cancer: the PANDORA trial
2023-10-0117
OAAI
Adverse events during first-line treatments for mCRC: The Toxicity over Time (ToxT) analysis of three randomised trials
2023-08-010
PRE
Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments

血浆BRAF-V600E等位基因分数作为BRAF组合治疗转移性结直肠癌的预后因素

2023-06-0136
OA
Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study
2023-04-2118
OAAI
Primary tumor resection (PTR) in metastatic colorectal cancer (mCRC) patients (pts) treated with upfront chemotherapy (CT) plus bevacizumab (BEV): A pooled analysis of TRIBE and TRIBE2 studies
2022-09-010
PRE
Prognostic and Predictive Role of Body Mass Index (BMI) in Metastatic Colorectal Cancer (mCRC): A Pooled Analisys of Tribe and Tribe-2 Studies by GONO
2022-09-015
PRE
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies
2022-07-019
PRE
Encorafenib plus cetuximab treatment in BRAF V600-Emutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case series
2022-06-019
OAAI
An immune-related gene expression profile predicts the efficacy of adding atezolizumab to first-line FOLFOXIRI/bevacizumab in metastatic colorectal cancer: A translational analysis of the phase II randomized AtezoTRIBE study
2022-06-010
OA